P-48 Study of paclitaxel and ramucirumab as second-line therapy after failure of FOLFOX-6 regimen in metastatic stomach carcinoma patients

Abstract

Second-line therapy of metastatic stomach cancer patients with ramucirumab in combination with paclitaxel has been proven to prolong overall survival (OS) in patients with pretreated metastatic gastric adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel after failure of FOLFOX-6 (platinum- and 5-FU-containing chemotherapy) regimen. This study was undertaken to assess the efficacy and safety of ramucirumab and paclitaxel regimen in this setting. In this retrospective study, patients with metastatic gastric adenocarcinoma, with performance status ≤2, who progressed on first-line FOLFOX-6-based therapy, were enrolled from May 2018 to June 2020. Ramucirumab and paclitaxel-based treatment was administered until progression or unacceptable toxicity. Statistical analysis was performed with the statistical software SPSS version 27. A total of 25 patients were enrolled. The median age was 55 yrs (28yrs – 68yrs), out of which 16 (64%) were males and 9 (36%) were females. The median no. of cycles that could be given were 3.5 (1-7). The disease control rate was seen in 15 (60%) patients, with CR in none, PR in 7 (28%), SD in 8 (32%), and PD in 10 (40%) patients. The median PFS was 3.4 months, median OS was 6.6 months. The main grade 3/4 side effect seen was neutropenia. The majority of patients (48%) had grade 1/2 peripheral neuropathy. Ramucirumab and paclitaxel combination is an effective and well tolerated regimen as a second-line treatment in metastatic gastric adenocarcinoma patients.